The introduction of maintenance poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors have represented an important treatment option for ovarian cancer. This educational meeting discussed the current landscape of ovarian cancer in New Zealand, and included practical strategies from overseas experts on optimising outcomes with first-line PARP inhibitors. This was a GSK medical education activity.
Please login below to download this issue (PDF)